Tacrolimus in combination with FTY720--an analysis of renal and blood parameters.
Calcineurin inhibitors (CNIs) are routinely used in immunosuppressive therapy and both Cyclosporine (CsA) and Tacrolimus (FK506) show similar efficacies to prevent rejection and death within the first year after organ transplantation. However, their use is limited by side effects such as kidney damage, hypertension, onset of diabetes and hyperlipidemia. It is a consensus that compared with CsA, FK506 causes less changes in blood pressures, serum lipids and renal function. Nevertheless, FK506 use is associated with a higher incidence of post-transplant diabetes mellitus (PTDM). FTY720 is a new compound that has shown a protective effect in animal models with respect to rejection in transplantation, ischemia-reperfusion injury, autoimmune diseases and tumor development. FTY720 acts by altering lymphocytes homing from blood to peripheral lymphoid organs. In mice, FTY720 administered in combination with CsA during 21 days has prolonged skin allograft survival without causing significant renal changes. In a model of CsA-induced chronic nephropathy in rats, FTY720 administration prevented renal injury suggesting benefit from using a combination of these drugs. In a canine kidney allograft model, FTY720 in combination with low doses of CsA or FK506 showed an addictive anti-rejection effect without causing critical adverse effects. We therefore, investigated whether 21 days of FTY720 administration in association with FK506 could prevent renal damage and development of diabetes in mice. Mice receiving FK506 alone or FTY720 + FK506 during 21 days showed changes in kidney function and structure besides an increase in blood glucose and lymphopenia. The FTY720 + FK506 combination requires further investigation with an aim toward understanding the mechanisms involved with respect to side effects.
Gallo
Ana Paula
AP
FAMERP São José do Rio Preto Medical School, Av.Brig.Faria Lima, 5416, Rua Francisco Giglioti, 160 ap 71, São Jose do Rio Preto, SP 15090-000, Brazil.
Silva
Lea Bueno Lucas
LB
Franco
Marcello
M
Burdmann
Emmanuel Almeida
EA
Bueno
Valquiria
V
D000818:Animals; D015415:Biomarkers / Q000097:blood* / Q000652:urine; D001786:Blood Glucose / Q000032:analysis; D003404:Creatinine / Q000097:blood / Q000652:urine; D003920:Diabetes Mellitus / Q000139:chemically induced; D004231:Diuresis / Q000187:drug effects; D004357:Drug Synergism; D000068876:Fingolimod Hydrochloride; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000633:toxicity; D007668:Kidney / Q000187:drug effects* / Q000502:physiology; D018655:Lymphocyte Count; D008231:Lymphopenia / Q000139:chemically induced; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011188:Potassium / Q000097:blood; D011409:Propylene Glycols / Q000494:pharmacology* / Q000633:toxicity; D012964:Sodium / Q000097:blood / Q000652:urine; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D016559:Tacrolimus / Q000494:pharmacology* / Q000633:toxicity
D015415:Biomarkers; D001786:Blood Glucose; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D012964:Sodium; D003404:Creatinine; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; D011188:Potassium; D016559:Tacrolimus